Show simple item record

dc.contributor.authorAsli, IN
dc.contributor.authorMosaffa, N
dc.contributor.authorMogharrabi, M
dc.contributor.authorHooman, A
dc.contributor.authorTabei, F
dc.contributor.authorJavadi, H
dc.contributor.authorShafei, B
dc.contributor.authorSeyedabadi, M
dc.contributor.authorAssadi, M
dc.date.accessioned2018-08-26T08:38:50Z
dc.date.available2018-08-26T08:38:50Z
dc.date.issued2010
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/52968
dc.description.abstractObjective: We evaluated the potential detrimental cytogenetic effects of 99mTc-methoxyisobutyl isonitrile (MIBI) and 131I on patients who were exposed to the radiopharmaceutics for cardiac imaging or thyroid cancer therapy, respectively. Methods: Mononuclear leukocytes were isolated both before and after radiopharmaceutical administration and subsequently cultured. Micronuclei frequency was then assessed and microscopic evaluation of apoptosis was conducted. Results: Small statistically insignificant augmentation in the percentage of micronuclei from 10.9 آ± 3.8 to 11.3آ±2.4% was observed in the 99mTc-MIBI group. In contrast, 131I elicited a notable augmentation of micronuclei from 6.3آ± 2.2 to 9.6آ± 3.1 at 3.7GBq, and 6 آ±1.5 to 9.2آ±2.7 at 5.55GBq (P <0.05). Conclusion: Our results showed that there were no remarkable alterations either in the micronuclei incidence or in the percentage of apoptotic lymphocytes after in-vivo exposure to radiopharmaceutical imaging, which provides evidence to reduce the growing concern about the safety issue of cardiac imaging with 99mTc-MIBI, whereas the deleterious effects of 131I must be considered when it is applied to thyroid cancer treatment. é 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
dc.language.isoEnglish
dc.relation.ispartofNuclear Medicine Communications
dc.subjectiodine 131
dc.subjectmethoxy isobutyl isonitrile technetium tc 99m
dc.subjectdiagnostic agent
dc.subjectmethoxy isobutyl isonitrile technetium tc 99m
dc.subjectradioactive iodine
dc.subjectadult
dc.subjectapoptosis
dc.subjectarticle
dc.subjectcancer therapy
dc.subjectcardiac imaging
dc.subjectchromosome aberration
dc.subjectclinical article
dc.subjectcytogenetics
dc.subjectdrug exposure
dc.subjectdrug megadose
dc.subjectdrug safety
dc.subjectfemale
dc.subjecthuman
dc.subjecthuman cell
dc.subjectleukocyte culture
dc.subjectmale
dc.subjectmicronucleus test
dc.subjectmononuclear cell
dc.subjectthyroid cancer
dc.subjectcell differentiation
dc.subjectchromosome aberration
dc.subjectgenetics
dc.subjectmethodology
dc.subjectmiddle aged
dc.subjectmyocardial perfusion imaging
dc.subjectpathology
dc.subjectradiation dose
dc.subjectradiation exposure
dc.subjectthyroid tumor
dc.subjectAdult
dc.subjectCell Differentiation
dc.subjectChromosome Aberrations
dc.subjectFemale
dc.subjectHumans
dc.subjectIodine Radioisotopes
dc.subjectMale
dc.subjectMicronucleus Tests
dc.subjectMiddle Aged
dc.subjectMyocardial Perfusion Imaging
dc.subjectRadiation Dosage
dc.subjectTechnetium Tc 99m Sestamibi
dc.subjectThyroid Neoplasms
dc.titleChromosome aberrations after high-dose 131I and 99mTc-MIBI administration using a micronucleus assay
dc.typeArticle
dc.citation.volume31
dc.citation.issue4
dc.citation.spage307
dc.citation.epage310
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.1097/MNM.0b013e3283354c9e


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record